FDA approves GSK's JAK inhibitor for rare blood cancer after three-month delay
The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval marks a major turnaround for the drug, which had failed earlier studies and was dumped by Gilead for a mere $3 million in 2018.
Momelotinib will be marketed as Ojjaara and the wholesale acquisition cost for a 30-tablet bottle will be $26,900, GSK announced Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.